AxoGen, Inc. (NASDAQ:AXGN) Short Interest Update

AxoGen, Inc. (NASDAQ:AXGN) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,130,000 shares, a drop of 8.1% from the October 15th total of 1,230,000 shares. Based on an average trading volume of 430,300 shares, the short-interest ratio is currently 2.6 days.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. JMP Securities raised their price target on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th. StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $15.00.

Hedge Funds Weigh In On AxoGen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC raised its stake in AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 2,076 shares during the period. nVerses Capital LLC acquired a new stake in AxoGen in the 3rd quarter valued at $56,000. Koss Olinger Consulting LLC acquired a new stake in AxoGen in the 2nd quarter valued at $75,000. Oppenheimer & Co. Inc. bought a new stake in AxoGen during the 3rd quarter valued at $156,000. Finally, Lazard Asset Management LLC raised its holdings in AxoGen by 30.1% during the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after buying an additional 2,671 shares during the last quarter. Institutional investors own 80.29% of the company’s stock.

AxoGen Stock Up 1.4 %

Shares of NASDAQ AXGN opened at $12.64 on Monday. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm has a market cap of $556.26 million, a PE ratio of -39.50 and a beta of 1.13. The company’s fifty day simple moving average is $13.79 and its 200 day simple moving average is $10.38. AxoGen has a 12-month low of $5.43 and a 12-month high of $15.90.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.